background
given
possibl
human
pandem
fact
recent
virus
resist
antivir
drug
newer
strategi
effect
therapi
warrant
previou
studi
show
singl
mab
immun
prophylaxi
protect
infect
singl
mab
may
effect
neutral
broad
rang
differ
strain
control
potenti
neutral
escap
mutant
methodsprincip
find
select
two
mab
recogn
differ
epitop
hemagglutinin
molecul
two
mab
could
neutral
vitro
escap
mutant
combin
could
effect
neutral
virus
clade
influenza
virus
combin
chimer
mab
administ
passiv
pre
post
challeng
mous
lethal
dose
hpai
influenza
virus
could
protect
mice
two
differ
clade
virus
clade
also
test
efficaci
singl
dose
combin
mab
versu
two
dose
two
dose
combin
therapi
affect
earli
clearanc
viru
lung
could
complet
prevent
lung
patholog
infect
mice
escap
variant
detect
therapi
conclusionssignific
studi
provid
proof
concept
synergist
action
two
mab
combin
requir
prevent
gener
escap
mutant
also
enhanc
therapeut
efficaci
passiv
therapi
infect
combin
therapi
may
allow
lower
dose
antibodi
administ
passiv
therapi
influenza
infect
henc
made
avail
reduc
econom
cost
outbreak
recent
emerg
strain
influenza
viru
high
mortal
caus
human
rais
concern
possibl
futur
influenza
pandem
present
vaccin
strategi
hinder
antigen
variat
influenza
strain
vaccin
strategi
requir
endogen
synthesi
antibodi
provid
immedi
protect
need
infect
event
pandem
antivir
therapi
receiv
much
attent
situat
howev
current
avail
antivir
treatment
option
limit
isol
drugresist
viral
strain
recent
past
warrant
urgent
need
altern
strategi
treatment
prophylaxi
passiv
administr
antibodi
neutral
epitop
may
attract
altern
activ
vaccin
human
particular
individu
high
risk
influenza
infect
viz
immunocompromis
patient
elderli
respond
well
activ
immun
antibodi
base
therapi
one
altern
approach
immunoprophylaxi
treatment
influenza
infect
passiv
administr
polyclon
antibodi
shown
protect
sever
nonprim
human
model
infect
passiv
immun
transfus
human
convalesc
sera
associ
reduct
mortal
influenza
pandem
shown
effect
influenza
viral
infect
equin
f
ab
fragment
specif
use
efficaci
prophylaxi
therapi
mous
model
murin
monoclon
antibodi
mab
fusion
peptid
hemagglutinin
ha
influenza
shown
passiv
transfer
experi
protect
mice
infect
reduct
viral
replic
thu
passiv
administr
mab
prior
influenza
infect
potenti
advantag
provid
high
titer
antibodi
suscept
individu
immedi
murin
mab
use
initi
clinic
trial
efficaci
mab
hamper
sever
problem
includ
diminish
serum
halflif
develop
human
antimous
antibodi
hama
counter
problem
sever
strategi
devis
includ
gener
chimer
human
human
mab
current
lot
focu
therapeut
approach
use
neutral
antibodi
protein
influenza
viru
protein
easi
target
surfac
viru
antibodi
protein
neutral
viru
effici
mab
prophylaxi
target
ha
protein
may
effect
mean
control
influenza
outbreak
passiv
immunoprophylaxi
therapi
singl
neutral
human
human
mab
efficaci
lethal
challeng
specif
strain
viru
import
mab
product
offer
broad
protect
circul
strain
influenza
prevent
select
neutral
escap
mutant
vivo
singl
monoclon
antibodi
may
effici
meet
criteria
sever
factor
import
form
effect
combin
mab
prophylact
therapeut
regimen
influenza
infect
includ
inclus
ideal
pair
complement
monoclon
antibodi
optim
number
dose
time
interv
dose
durat
therapi
mab
includ
combin
therapi
target
distinct
region
antigen
non
overlap
epitop
abl
complement
treatment
regimen
present
studi
focu
select
pair
mab
two
differ
neutral
epitop
chimer
evalu
prophylact
therapeut
efficaci
combin
therapi
use
chimer
mab
murin
model
experiment
challeng
two
distinct
phylogenet
clade
highli
pathogen
virus
acommon
obtain
agrifood
veterinari
author
ava
singapor
virus
differ
phylogenet
clade
subclad
rescu
revers
genet
briefli
hemagglutinin
ha
neuraminidas
na
gene
virus
clade
tabl
synthes
genscript
usa
base
sequenc
ncbi
influenza
databas
synthet
ha
na
gene
clone
dualpromot
plasmid
influenza
revers
genet
dualpromot
plasmid
obtain
center
diseas
control
prevent
atlanta
ga
usa
reassort
virus
rescu
transfect
plasmid
contain
ha
na
along
remain
six
influenza
gene
deriv
apuerto
cocultur
mdck
cell
use
lipofectamin
invitrogen
corp
h
posttransfect
cultur
medium
inocul
embryon
egg
mdck
cell
ha
na
gene
reassort
virus
second
passag
sequenc
confirm
presenc
introduc
ha
na
gene
absenc
mutat
stock
virus
propag
allanto
caviti
dayold
embryon
egg
viru
contain
allanto
fluid
harvest
store
aliquot
viru
content
determin
standard
hemagglutin
ha
assay
experi
highli
pathogen
virus
conduct
biosafeti
level
contain
facil
complianc
cdcnih
recommend
balbc
mice
immun
twice
subcutan
interv
week
purifi
formalin
inactiv
antigen
adjuv
seppic
franc
mice
boost
viral
antigen
day
fusion
splenocyt
cell
fuse
cell
seed
plate
supernat
screen
immunofluoresc
assay
describ
hybridoma
produc
mab
clone
limit
dilut
least
three
time
posit
mab
test
hemagglutin
inhibit
activ
describ
immunoglobulin
select
posit
mab
isotyp
use
commerci
isotyp
kit
amersham
bioscienc
england
describ
manufactur
protocol
mdck
cell
cultur
plate
infect
aiv
strain
h
postinfect
cell
fix
paraformaldehyd
min
room
temperatur
wash
thrice
phosphat
buffer
salin
pb
ph
fix
cell
incub
hybridoma
cultur
supernat
h
rins
phosphat
buffer
salin
pb
incub
dilut
fluorescein
isothiocyan
fitc
conjug
rabbit
antimous
immunoglobulin
dako
denmark
cell
rins
pb
antibodi
bind
evalu
widefield
epifluoresc
microscopi
olympu
hemagglutin
inhibit
assay
hemagglutin
inhibit
hi
assay
perform
describ
previous
briefli
mab
serial
dilut
fold
vbottom
plate
mix
ha
unit
viru
plate
incub
min
room
temperatur
chicken
rbc
ad
well
hemagglutin
inhibit
endpoint
highest
mab
dilut
agglutin
observ
epitop
recogn
mab
map
character
escap
mutant
describ
previous
briefli
virus
incub
excess
mab
h
inocul
day
old
embryon
chicken
egg
isol
vivo
escap
mutant
lung
sampl
treat
mice
inocul
directli
embryon
egg
egg
incub
h
viru
harvest
use
clone
limit
dilut
embryon
chicken
egg
escap
mutant
plaqu
purifi
ha
gene
mutat
identifi
sequenc
compar
sequenc
parent
viru
design
express
vector
describ
briefli
human
antibodi
constant
region
encod
kappa
light
chain
heavi
chain
amplifi
clone
modifi
pcmvmycer
plasmid
intern
ribosom
entri
site
ire
encephalomyocard
viru
insert
uniqu
restrict
site
introduc
allow
insert
variabl
region
heavi
light
chain
frame
constant
region
mrna
prepar
mab
hybridoma
cell
use
first
strand
cdna
synthesi
random
hexam
total
cdna
use
templat
amplifi
variabl
heavi
light
chain
use
primer
protocol
mous
scfv
recombin
antibodi
phage
system
amersham
bioscienc
result
product
clone
pcrscript
stratagen
usa
sequenc
sequencespecif
primer
design
use
amplif
variabl
region
clone
express
vector
express
construct
lead
product
chimer
antibodi
contain
sequenc
mous
variabl
region
murin
sequenc
human
constant
region
chimer
antibodi
express
use
freestyl
express
system
invitrogen
usa
obtain
antibodi
produc
defin
serumfre
medium
mention
construct
transfect
cell
use
invitrogen
usa
supernat
collect
h
transfect
chimer
antibodi
chmab
chmab
purifi
use
protein
sepharos
bead
millipor
puriti
chimer
antibodi
confirm
sdspage
immunoblot
analysi
use
hrp
label
antihuman
ig
dako
use
confirm
introduct
human
constant
region
neutral
activ
chimer
antibodi
strain
analyz
microneutr
assay
previous
describ
briefli
mab
serial
twofold
dilut
incub
tissu
cultur
infecti
dose
tcid
differ
clade
strain
h
room
temperatur
plate
duplic
onto
mdck
cell
grown
plate
tcid
strain
mdck
cell
cultur
determin
reed
muench
method
neutral
titer
assess
highest
mab
dilut
cytopath
effect
observ
light
microscopi
group
spf
femal
balbc
mice
age
week
use
challeng
studi
mice
n
per
group
inocul
intranas
mld
mous
lethal
dose
two
differ
strain
clade
clade
anim
experi
carri
accord
guid
anim
experi
perform
niid
experiment
protocol
review
approv
institut
anim
care
use
committe
temasek
life
scienc
laboratori
nation
univers
singapor
determin
prophylact
efficaci
mice
pretreat
intraperiton
mgkg
mgkg
mgkg
mg
kg
pb
combin
chmab
prior
viral
challeng
mgkg
irrelev
monoclon
antibodi
specif
porcin
circoviru
prepar
similar
manner
use
measur
nonspecif
protect
h
mice
challeng
mld
two
differ
strain
mice
observ
daili
monitor
bodi
weight
mortal
anim
die
day
challeng
determin
therapeut
efficaci
chmab
group
mice
experiment
infect
mld
two
differ
strain
twenti
four
hour
viral
infect
mice
treat
via
intraperiton
rout
mgkg
mgkg
mgkg
mgkg
pb
combin
chmab
mgkg
irrelev
monoclon
antibodi
specif
porcin
circoviru
prepar
similar
manner
use
measur
nonspecif
protect
doubl
therapi
experi
differ
set
mice
treat
similar
dose
chimer
mab
h
h
viral
challeng
one
addit
group
mice
challeng
mld
viru
clade
treat
one
day
viral
challeng
chmab
done
compar
therapeut
efficaci
one
mab
combin
chmab
separ
set
mice
maintain
experiment
group
infect
clade
determin
viral
titer
histopatholog
experi
day
post
viral
challeng
mice
euthan
lethal
dose
sodium
pentobarbit
determin
viral
titer
lung
asept
remov
tissu
homogen
ml
dulbecco
minim
essenti
medium
dmem
supplement
antibioticantimycot
solut
gibcobrl
usa
achiev
serial
dilut
suspens
lung
sampl
titrat
monolay
mdck
cell
viral
titer
calcul
use
method
reed
muench
method
express
log
tcid
gram
tissu
limit
viru
detect
lung
tissu
specimen
histopatholog
mice
necropsi
lung
store
wtvol
neutral
buffer
formalin
embed
paraffin
section
section
stain
hematoxylin
eosin
prior
light
microscopi
examin
evalu
lung
patholog
panel
seven
neutral
mab
influenza
hemagglutinin
ha
screen
high
hemagglutin
inhibit
titer
differ
clade
virus
base
result
hi
assay
mab
chosen
studi
due
high
hi
activ
data
shown
wide
rang
rescu
reassort
virus
differ
clade
mab
found
isotyp
amino
acid
involv
form
epitop
mab
analyz
use
select
neutral
escap
mutant
sequenc
complet
ha
gene
isol
multipl
escap
variant
carri
singl
point
mutat
amino
acid
posit
arg
trp
ser
arg
exclud
signal
peptid
similar
analysi
mab
reveal
involv
amino
acid
ser
asn
form
epitop
two
mab
found
recogn
nonoverlap
epitop
react
virus
differ
clade
avail
laboratori
escap
mutant
mab
recogn
mab
vice
versa
henc
mab
thought
good
potenti
use
combin
therapi
infect
ascertain
mab
combin
subject
hemagglutin
inhibit
assay
wide
rang
virus
differ
clade
hemagglutin
inhibit
assay
use
combin
mab
elicit
titer
test
strain
tabl
conclud
mab
complement
good
pair
use
therapi
influenza
chimer
monoclon
antibodi
chmab
gener
mab
constant
region
replac
human
origin
variabl
region
remain
murin
origin
chimer
mab
gener
way
human
chimer
antibodi
still
retain
origin
properti
murin
mab
result
shown
vitro
microneutr
titer
drop
littl
compar
murin
mab
still
retain
signific
viral
neutral
activ
tabl
prophylact
efficaci
combin
chmab
evalu
challeng
clade
clade
virus
group
mice
n
inocul
via
intraperiton
rout
differ
concentr
mgkg
mgkg
mgkg
combin
mab
h
prior
viral
challeng
neg
control
group
mice
treat
nonspecif
mab
show
rapid
declin
bodi
weight
die
complic
associ
infect
day
post
challeng
group
mice
pretreat
singl
dose
mgkg
chmab
show
less
fig
loss
bodi
weight
concentr
provid
protect
clade
virus
fig
moreov
chmab
mgkg
provid
suffici
protect
dose
depend
manner
group
mice
show
less
loss
bodi
weight
even
low
concentr
mgkg
chmab
could
provid
protect
clade
fig
clade
fig
virus
respect
mice
group
show
loss
bodi
weight
fig
order
evalu
therapeut
potenti
singl
mab
influenza
infect
treat
mice
chmab
alon
one
day
viral
challeng
viru
observ
mgkg
chmab
fig
could
protect
mice
viral
infect
howev
mice
could
protect
mgkg
mg
therapeut
antibodi
respect
determin
singl
dose
treatment
could
elicit
effici
protect
lethal
viral
infect
one
set
mice
treat
singl
dose
h
viral
challeng
mab
efficaci
singl
dose
compar
mice
treat
doubl
dose
h
h
viral
infect
chmab
group
mice
treat
either
singl
dose
doubl
dose
mgkg
chmab
lost
less
origin
bodi
weight
day
challeng
provid
protect
clade
fig
virus
fig
moreov
group
mice
receiv
doubl
dose
chmab
hour
interv
regain
bodi
weight
rapidli
within
day
compar
mice
receiv
singl
dose
regain
bodi
weight
day
viral
infect
fig
mice
treat
doubl
dose
mgkg
chmab
also
lost
less
origin
bodi
weight
provid
protect
virus
howev
mice
treat
singl
dose
concentr
chmab
show
consider
weight
loss
provid
protect
even
low
concentr
mgkg
two
dose
combin
chmab
could
provid
protect
mld
virus
contrast
mice
treat
singl
dose
concentr
show
loss
bodi
weight
fig
provid
moder
protect
virus
fig
histopatholog
studi
follow
lung
mice
treat
singl
doubl
dose
combin
mab
h
post
viral
infect
clade
viru
day
pi
lung
untreat
mice
mice
treat
irrelev
mab
pulmonari
lesion
consist
moder
sever
necrot
bronchiti
moder
sever
histiocyt
alveol
associ
pulmonari
edema
fig
uninfect
mice
lack
lesion
lung
fig
mice
treat
two
dose
mgkg
show
lung
patholog
look
similar
uninfect
control
fig
mice
treat
singl
dose
mgkg
chmab
minim
bronchiti
fig
studi
kinet
viral
replic
measur
viral
titer
lung
infect
treat
mice
day
viru
titer
elev
day
viral
challeng
viral
titer
highest
infect
untreat
control
day
anim
succumb
infect
day
viral
challeng
fig
mice
treat
singl
dose
mgkg
combin
treat
doubl
dose
mgkg
mgkg
show
undetect
viral
titer
day
howev
mice
treat
dose
show
undetect
titer
day
fig
howev
day
mice
treat
dose
mgkg
much
lower
viral
titer
treat
singl
dose
result
show
even
lowest
concentr
mgkg
doubl
dose
mab
combin
could
neutral
viru
much
effici
singl
dose
fig
escap
mutant
isol
lung
mice
treatment
singl
dose
chmab
even
concentr
mgkg
escap
mutant
found
common
mutat
ser
escap
mutant
observ
mice
treat
mgkg
chmab
among
major
individu
mice
show
singl
point
mutant
escap
mab
mice
show
escap
mutant
mutat
two
point
interestingli
escap
mutant
isol
lung
group
mice
treat
doubl
dose
chmab
h
interv
highli
neutral
antibodi
respons
protect
immun
influenza
infect
associ
hemagglutinin
ha
glycoprotein
therefor
protein
major
focu
therapeut
intervent
influenza
infect
influenza
vaccin
target
protein
induc
immun
respons
host
mainli
form
neutral
antibodi
base
respons
howev
whenev
immedi
protect
becom
essenti
time
induc
antibodi
respons
best
altern
far
passiv
immun
also
sinc
drug
resist
strain
virus
emerg
vital
explor
mean
therapi
infect
passiv
monoclon
antibodi
base
therapi
viabl
option
investig
previou
studi
proven
efficaci
human
human
monoclon
antibodi
therapi
murin
model
infect
howev
studi
discuss
applic
singl
monoclon
antibodi
infect
strain
viru
singl
monoclon
antibodi
may
suffici
protect
circul
strain
also
util
singl
mab
one
epitop
result
select
pressureinduc
escap
viru
point
mutat
alter
antibodi
bind
mention
studi
infect
look
aspect
great
detail
view
proven
effici
passiv
prophylaxi
therapi
infect
anim
model
use
singl
mab
evalu
prospect
use
combin
monoclon
antibodi
tackl
issu
pose
use
singl
mab
therapi
evid
studi
synergist
action
two
mab
combin
requir
prevent
gener
escap
mutant
also
enhanc
therapeut
efficaci
infect
chose
mab
base
recognit
nonoverlap
noncompet
epitop
combin
mab
could
neutral
strain
phylogenet
distinct
clade
also
escap
mutant
gener
mab
could
effici
neutral
deduc
combin
mab
would
effici
therapi
strain
henc
use
combin
mab
prophylaxi
therapi
mous
model
infect
result
present
studi
demonstr
passiv
administr
combin
two
differ
neutral
chimer
mab
effect
protect
highli
pathogen
infect
administ
either
prophylaxi
therapeut
observ
mgkg
chmab
requir
protect
mice
singl
mab
use
howev
combin
mab
use
condit
viral
challeng
mgkg
singl
dose
mgkg
doubl
dose
need
offer
complet
protect
administr
two
dose
combin
show
better
protect
viral
load
lung
significantli
reduc
compar
administr
singl
dose
moreov
doubl
dose
combin
mab
control
immun
escap
escap
mutant
isol
lung
group
mice
treat
h
interv
two
dose
observ
gener
escap
mutant
vivo
case
whenev
singl
monoclon
antibodi
use
therapi
data
shown
howev
use
two
monoclon
antibodi
combin
also
show
gener
escap
mutant
whenev
subneutr
concentr
mab
use
use
higher
concentr
singl
dose
mgkg
reduc
possibl
may
depend
amount
complementari
circul
mab
present
system
could
effect
neutral
escap
mutant
due
one
mab
base
evid
bodi
weight
mice
mice
healthi
enough
singl
administr
escap
mutant
clear
activ
immun
system
mice
given
half
life
mab
limit
evid
two
dose
mab
combin
work
much
better
way
provid
better
safeti
emerg
escap
variant
high
rate
emerg
escap
mutant
virus
evid
antibodi
highli
neutral
henc
forc
virus
adapt
fact
use
chmab
combin
two
dose
give
rise
escap
mutant
proof
antibodi
complementari
henc
offer
complet
protect
mice
previou
studi
virus
shown
combin
two
two
mab
direct
differ
epitop
could
lead
two
ten
fold
increas
neutral
titer
provid
greater
protect
mani
diseas
moreov
meulen
et
al
report
much
better
control
potenti
neutral
escap
variant
could
achiev
antibodi
combin
sar
coronaviru
howev
studi
done
far
demonstr
efficaci
combin
therapi
infect
though
dose
antibodi
deliv
complet
protect
mice
quit
high
believ
improv
antibodi
well
inclus
antibodi
cocktail
ensur
better
protect
data
provid
rational
develop
combin
mab
human
prophylaxi
therapeut
combin
two
mab
expand
breadth
protect
high
level
efficaci
safeti
associ
potenti
immun
escap
variant
also
combin
therapi
may
allow
lower
dose
antibodi
administ
passiv
therapi
influenza
infect
henc
made
avail
reduc
econom
cost
outbreak
futur
may
possibl
gener
human
monoclon
antibodi
mab
cdr
complementar
determin
region
graft
facilit
use
nonprim
human
clinic
trial
